The p110δ subunit of phosphatidylinositol-3-OH kinase (PI(3)K) is selectively expressed in leukocytes and is critical for lymphocyte biology. Here we report fourteen patients from seven families who were heterozygous for three different germline, gain-of-function mutations in PIK3CD (which encodes p110δ). These patients presented with sinopulmonary infections, lymphadenopathy, nodular lymphoid hyperplasia and viremia due to cytomegalovirus (CMV) and/or Epstein-Barr virus (EBV). Strikingly, they had a substantial deficiency in naive T cells but an over-representation of senescent effector T cells. In vitro, T cells from patients exhibited increased phosphorylation of the kinase Akt and hyperactivation of the metabolic checkpoint kinase mTOR, enhanced glucose uptake and terminal effector differentiation. Notably, treatment with rapamycin to inhibit mTOR activity in vivo partially restored the abundance of naive T cells, largely 'rescued' the in vitro T cell defects and improved the clinical course.
memory precursor effector cells 16 . When Akt-mTOR signaling is sustained, a transcriptional program that promotes effector function drives cells toward differentiation into terminal effector cells at the expense of memory formation 17, 18 . Mounting evidence suggests that effector cells must 'reset' their metabolic activity to become memory cells. Naive CD8 + T cells use fatty-acid oxidation and mitochondrial respiration to meet their relatively low energy demands; however, after the activation of naive cells, a switch to lipid synthesis and glycolysis is necessary to rapidly provide the cell with sufficient energy to carry out effector functions. To survive and contribute to the memory pool, effector CD8 + T cells must revert back to the catabolic processes of fatty-acid oxidation and mitochondrial respiration 12 . The Akt-mTOR pathway is a central mediator of that switch, as it promotes glucose uptake, glycolysis and lipid synthesis, all processes crucial for the differentiation of CD8 + T cells 19 . Therefore, it is of great interest to determine how alterations in these metabolic pathways in cells of the immune system can affect T cell differentiation and human health. Here we describe a group of patients with combined immunodeficiency and lymphoproliferative disease who share gain-of-function mutations in PIK3CD (which encodes p110d). Those mutations resulted in hyperactivation of mTOR signaling and skewed the differentiation of CD8 + T cells to short-lived effector cells with severely impaired development of functional memory T cells and B cells.
RESULTS

Immunodeficiency, memory abnormalities and effector skewing
We evaluated nine patients from seven unrelated families of different ethnic and racial backgrounds who presented with childhood onset sinopulmonary infections, lymphoproliferation ( Supplementary Fig. 1a,b) , chronic viremia due to Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV), and distinctive nodular lymphoid (CD3 + and CD20 + ) hyperplasia of mucosal surfaces ( Table 1, Fig. 1a , Supplementary Table 1 the generation of memory 6 . The metabolic checkpoint kinase mTOR (mechanistic target of rapamycin), which is activated by PI(3)K, has a prominent role in promoting dynamic changes in T cell metabolism 7, 8 . PI(3)K has been described as activating mTOR complex 2 (composed of mTOR, Rictor and GbL) by promoting its association with ribosomes 9 . Moreover, the PtdIns(3,4,5)P 3 generated by PI(3)K recruits both the kinase PDK1 and the kinase Akt (PKB) and thereby enables full activation of Akt through phosphorylation at Thr308 (by PDK1) and Ser473 (by mTOR complex 2) 10, 11 . In its active form, Akt activates mTOR complex 1 (mTORC1; composed of mTOR, Raptor and GbL), which leads to phosphorylation of the translation-initiation inhibitor 4E-BP1 and the kinase p70S6K to promote protein translation 12 . Phosphorylation of 4E-BP1 results in its release from the translation-initiation factor eIF4E and promotes cap-dependent translation, whereas phosphorylation of p70S6K activates the ribosomal protein S6 to enhance the translation of ribosomal proteins and elongation factors. One of the proteins whose expression is increased by mTORC1 activity is the transcription factor HIF-1a, a key regulator of glycolysis 13 . Thus, in cells with high PI(3)K-Akt-mTOR activity, a metabolic shift toward glycolysis would be expected, and indeed this occurs after the differentiation of naive T cells into effector T cells 14 . In addition to enhancing HIF-1a expression, mTORC1 activity promotes the translation and stability of the tumor suppressor p53 and has been linked to the role of p53 in inducing cellular senescence 15 . However, it is unknown how constitutive activation of the Akt-mTOR pathway affects T cell function and immunity in humans.
When a naive T cell encounters antigen, a differentiation process ensues that generates both short-lived effector cells that respond to the acute phase of infection as well as long-lived memory cells that ensure a rapid and vigorous immune response if the same antigen is reencountered. For CD8 + T cells, the Akt-mTOR pathway has been highlighted as a critical mediator of differentiation into short-lived effector cells versus showed enrichment for immature transitional CD10 + B cells (Fig. 1d) .
We observed progressive CD4 + T cell lymphopenia ( Fig. 1e ) with normal to high CD8 + T cell counts ( Fig. 1f and Table 1 ). The responses of T cells from patients to in vitro mitogen stimulation were poor ( Supplementary  Fig. 1c ), as were their responses to recall challenge with tetanus ( Fig. 1g) . Notably, these patients had a reversed ratio of CD4 + T cells to CD8 + T cells and a much lower abundance of CD45RA + CCR7 + naive T cells, with a correspondingly greater abundance of CD45RA -CCR7 -effector memory T cells (T EM cells) and CD45RA + effector memory T cells (T EMRA cells), relative to those of healthy control subjects (Fig. 1h,i and Supplementary Fig. 1d) . Because patients present with sinopulmonary infections and had a deficiency in memory B cells and overrepresentation of transitional B cells and Supplementary Fig. 1 ). We also observed autoimmune cytopenia in several patients (Supplementary Table 1 ). Of relevance, EBV-driven B cell lymphoma occurred in two index patients (C.1 and F.II.1), one of whom (F.II.1) was diagnosed with an EBV + nodular sclerosis form of classical Hodgkin lymphoma (Fig. 1b) , which is characteristically observed in immunodeficient patients 20 . Additionally, a 12-year-old patient (B.III.1) with extensive nonmalignant lymphoproliferation represents the third generation of a family in which two other members had EBV-associated lymphomas (in support of an autosomal-dominant inheritance pattern). Although lymph node architecture was preserved, B cell follicles had prominent germinal centers with no mantle zones and no detectable staining of immunoglobulin G (IgG) (Fig. 1c) bers heterozygosity for one of the following three PIK3CD mutations, each located in a different domain (notation based on GenBank accession code NM_005026). One index patient had a C-to-A mutation at cDNA position 1002 that resulted in the amino acid substitution N334K in the C2 domain. Seven patients (three index patients plus four affected relatives, two of whom have not been fully evaluated) had a G-to-A mutation at nucleotide 1573 that resulted in an E525K substitution in the helical domain. Six patients (three index patients plus three deceased, affected relatives) had a G-to-A mutation at 3061 that resulted in an E1021K substitution in the C-lobe of the kinase domain ( Fig. 2a,b ). All patients with a mutation were found to have characteristics of the disease when they were evaluated. The three mutations were predicted to be damaging by functional prediction algorithms (including SIFT, PP2, LRT, MutationTaster and MutationAssessor). We suspected these were gain-of-function mutations on the basis of protein-structure analysis and comparison with homologous gain-of-function mutations in the gene encoding p110a described in human cancer cells 22 ( Supplementary Fig. 3 and Supplementary Table 3 ). Since p110d and p110a share 72% amino acid sequence identity or similarity, as noted above, we were able to confidently map the substitutions N334K and E525K in patient p110d to the same substitutions at the homologous residues 345 and 545, respectively, of mutant p110a already described as encoded by gain- (Fig. 1d) , we further investigated those lymphocytes. We observed alterations in serum immunoglobulin concentrations in the patients, most with normal to elevated concentrations of IgM and reduced concentrations of IgA ( Supplementary Fig. 1e ). Serum concentrations of IgG were variable, but specific antibody titers were consistently low in the patients (data not shown). We observed a normal frequency of total B cells in the blood ( Supplementary  Fig. 2a ) but higher expression of IgM (data not shown) and CD5 ( Supplementary Fig. 2b ), a marker whose expression is downregulated as B cells mature, on both transitional and naive B cells from patients. Consistent with the histology data ( Fig. 1c) , the contracted population of memory B cells in patients' peripheral blood had much lower frequencies of class-switched IgG + and IgA + cells (Supplementary Fig. 2c ).
In vitro analysis of naive B cell function revealed that they were able to undergo nearly normal proliferation in response to a variety of stimuli ( Supplementary Fig. 2d ), acquire expression of AICDA (which encodes the cytidine deaminase AID) ( Supplementary Fig.  2e ) and secrete IgM ( Supplementary Fig. 2f , left). However they were impaired in secreting class-switched immunoglobulin isotypes ( Supplementary Fig. 2f , middle and right). Memory B cells acted in a similar way, with normal secretion of IgM but impaired production of IgG and IgA ( Supplementary Fig. 2g ). Those in vitro findings were consistent with the in vivo data demonstrating diminished serum immunoglobulin and impaired humoral immune responses, which leads to susceptibility to sinopulmonary infections. Thus, this cohort of patients had combined immunodeficiency in T cells and B cells, impaired memory T cell responses with lymphoproliferation, and a striking inability to control infection with EBV and/or CMV.
Heterozygosity for gain-of-function mutations in PIK3CD PIK3CD encodes the PI(3)K subunit p110d, a protein of 1,044 amino acids with at least five domains identified by structure and function: an adaptor-binding domain, a Ras GTPase-binding domain, a PI(3) K-type C2 domain, a helical domain and a kinase domain with amino (N) and carboxyl (C) side lobes (Fig. 2a) . Through the use of wholeexome sequencing 21 and targeted Sanger sequencing (Supplementary Table 2 ), we detected in fourteen of these patients and family mem- 
mens from one or both parents were not accessible. The appearance of PIK3CD mutations in three different sites among seven unrelated families from different ethnic and racial backgrounds (Supplementary Table 1 ) eliminated the possibility of a founder effect, while the presence of the same mutation in multiple families suggested the occurrence of mutational 'hot spots' , as seen before in genetic diseases of the immune system 27,28 .
Next we sought to evaluate expression of p110d and test the hypothesis that PI(3)K was hyperactive in our patients. We examined abundance of p110d protein and phosphorylation of Akt at Ser473 in T cell blasts and peripheral blood mononuclear cells (PBMCs) from patients ( Fig. 2d and Supplementary Fig. 4a-c) . Expression of the each of the three mutant p110d proteins was normal; however, phosphorylation of Akt was higher than that in cells from healthy control subjects, before and after stimulation with antibody to CD3 (anti-CD3) ( Supplementary Fig. 4a,c) . We also found that phosphorylation of Akt at Thr308 was higher in T cell blasts from patients than in those from healthy control subjects (Supplementary Fig. 4d,e) . Moreover, the abundance of Foxo1, a substrate of Akt that is degraded when phosphorylated, was lower in T cell blasts from patients than in those from healthy control subjects, as assessed by immunoblot analysis (data not shown). To confirm that substitutions in p110d were responsible for the hyperactivation of Akt, we overexpressed N334K, E525K or of-function mutations in cancer [22] [23] [24] [25] . The substitution E1021K (in the kinase domain) has been reported before in a boy with primary B cell immunodeficiency 26 . Glu1021 of p110d corresponds to Asp1045 of p110a, which is two residues upstream of a known gain-of-function substitution (H1047R in p110a; Fig. 2b ) that reportedly increases the interaction of p110a with the cell membrane and thereby increases its activity by enhancing accessibility of the binding site to PtdIns(4,5) P 2 (ref. 23 ). The substitution of glutamic acid with lysine at residue 1021 of p110d (E1021K) resulted in a change in the logarithmic acid dissociation constant (pK a ) of +6.28, similar to the change in pK a that results from the histidine-to-arginine substitution at residue 1047 of p110a (H1047R; +6.48); this indicates the same increased propensity for interaction with the negatively charged phospholipid head groups of the inner leaflet of the plasma membrane. Moreover, two additional reports have demonstrated that the H1047R substitution of p110a mimics binding to Ras-GTP to augment the catalytic activity of PI(3) K 25 and affects the conformation of the activation loop to promote kinase activity 22 , which suggests that the E1021K substitution of p110d in our patients may have multiple gain-of-function effects.
We confirmed that only two of the seven families had a de novo mutation in the index patient, and another three had confirmed affected members in multiple generations (Fig. 2c) . For the remaining two families, speci- Fig. 5d) . (e) Granzyme B expression in activated CD8 + T cells from a healthy control subject and patients A.1 and G.1 (quantification, Supplementary  Fig. 5e ). Supplementary Fig. 5h ). Data are representative of four independent experiments (a,c), six independent experiments with a total of eight patients (b), two independent experiments (d-f) or three independent experiments with four different patients (g). Fig. 1h and Supplementary Fig. 1d ), which suggested a terminally differentiated state. Correspondingly, in vitro activation of unsorted PBMCs with various stimuli revealed a reduced proliferative capacity and diminished secretion of interleukin 2 (IL-2) relative to those of cells from healthy controls, but activation of isolated naive CD4 + T cells did not (Fig. 3b,c and data not shown) ; however, the proliferation defect was 'rescued' by stimulation with beads coated with anti-CD2, anti-CD3 and anti-CD28 or with allogeneic PBMCs plus phytohemagglutinin (data not shown). As the composition of cells in the peripheral blood of patients was biased toward effector T cells, the defective proliferation was consistent with the well-described ability of naive T cells to proliferate better than differentiated effector cells. Also consistent with a T EM cell and/or T EMRA cell phenotype, activated patient CD8 + T cells exhibited characteristics of enhanced effector function. We found that expression of interferon-g, the transcription factor T-bet and granzyme B, as well as degranulation (as reflected by cycling of LAMP-1 (CD107a) after stimulation), were higher in cytotoxic T lymphocytes cultured from patients than in those from healthy control subjects (Fig. 3d-f and Supplementary  Fig. 5d-f) . We also assessed granzyme B expression after activation of purified naive CD8 + T cells and again observed higher expression in cells from patients than in those from healthy control subjects (data not shown). When we assessed the cytotoxic function of cytotoxic T lymphocytes from patients by anti-CD3-mediated redirected lysis of target cells (of the P815 mouse lymphoblast-like mastocytoma cell line), cells from patients exhibited a normal capacity to kill E1021K mutant p110d in PBMCs from healthy control subjects and found that the mutant p110d proteins induced hyperphosphorylation of Akt (Fig. 2e and Supplementary Fig. 4f ). We also confirmed that result by overexpression of mutant p110d in the H9 human T cell line (Supplementary Fig. 4g ). Moreover, we found that mutant p110d was able to interact with the p85a subunit as well as wild-type p110d did, as assessed by overexpression and coimmunoprecipitation (Supplementary Fig. 4h) . Thus, each subject in our patient cohort was heterozygous for an inherited or de novo gain-of-function mutation in the gene encoding p110d that led to expression of a hyperactive kinase that augmented the phosphorylation of Akt.
Expanded senescent CD8 + effector T cell populations
We next assessed the frequency of EBV-specific CD8 + T cells by staining PBMCs ex vivo with HLA tetramers loaded with lytic or latent EBV peptide antigens. Despite their uncontrolled infection with EBV, these patients generated normal to high frequencies of EBV-specific CD8 + T cells ( Fig. 3a and Supplementary Fig. 5a ). Tetramer-positive CD8 + T cells had an effector memory phenotype (CCR7 -CD45RA -) and were more activated, as shown by upregulation of expression of the costimulatory molecule CD38, than were cells from healthy control subjects (Supplementary Fig. 5b,c) . These data suggested that the PIK3CD mutations were unlikely to result in global impairment of the in vivo recognition of antigen by T cells.
Phenotypically, CD8 + T cells from patients appeared to be predominantly negative for expression of the chemokine receptor CCR7 (f) Glucose uptake in glucose-starved T cell blasts from a healthy control subject and patient G.1, measured by flow cytometry analysis of the fluorescent deoxyglucose analog 2-NBDG (quantification, Supplementary Fig. 8c ). Iso, isotype-matched control antibody. (g) Positron-emission tomography scanning of patient G.1 after administration of the glucose analog 18 F-fludeoxyglucose, showing glucose uptake. Data are representative of two independent experiments with five different healthy control subjects and five different patients (a), one experiment with three healthy control subjects and three patients (b), three independent experiments (c,e), two independent experiments (d), five independent experiments (f) or three independent experiments with one patient in each (g).
activation of mTORC1, glucose uptake was augmented in T cell blasts from patients with mutant p110d relative to that in cells from healthy control subjects ( Fig. 4f and Supplementary Fig. 8c ). Increased glucose uptake was also evident in the lymph nodes (most pronounced in the iliac chains and inguinal regions bilaterally) of patient G.1, as evaluated by positron-emission tomography scanning (Fig. 4g) , which suggested that mutant p110d drove the T cells into glycolytic metabolism. Notably, the patients with the most hyperphosphorylation of S6 and greatest glucose uptake (A.1 and G.1) were also the most severely affected clinically. Thus, activating p110d substitutions were associated with hyperactivity of the PI(3)K-Akt-mTOR signaling pathway in T cells, which led to enhanced glycolysis; this provided a mechanism for the predisposition to senescence.
( Supplementary Fig. 5g) . Notably, we found that expression of the senescence-associated marker CD57 was significantly higher on CD8 + T cells, but not on CD4 + T cells, from patients than on their counterparts from healthy control subjects 29 ( Fig. 3g, Table 1 and Supplementary Fig. 5h ). Of note, we observed normal to high expression of the cytotoxic lymphocyte-activating receptor NKG2D (data not shown) and variable expression of the T cell inhibitory receptor PD-1 on CD8 + T cells from patients (Supplementary Fig. 6 ). Hence, phenotypically and functionally, patient CD8 + T cells were mostly T EM cells and/or T EMRA cells with a low proliferative capacity but with certain aspects of high effector function characteristic of senescent effector cells.
Augmented mTOR signaling and glycolysis
To gain insight into how the p110d gain-of-function substitutions caused terminal differentiation and senescence, we examined signaling pathways downstream of PI(3)K. T cell antigen receptor (TCR)-induced calcium flux and translocation of the transcription factor NF-kB subunit p65 to the nucleus were normal in T cell blasts from patients (Fig. 4a,b) , which demonstrated that multiple aspects of TCR signaling were intact. Moreover, the expression of PTEN, the cell-cycle inhibitor p27 Kip1 and other signaling molecules was normal in T cells from patients (Supplementary Fig. 7 ). An important molecule activated downstream of PI(3)K and Akt in many cell types is mTOR, a serine-threonine kinase that modulates T cell metabolism and the effector differentiation of CD8 + T cells through the induction of glycolysis. We therefore hypothesized that hyperactive PI(3)K-Akt signaling was affecting T cell metabolism by stimulating the mTOR pathway. Consistent with our hypothesis, we observed more phosphorylation of the ribosomal protein S6 at Ser235 and Ser236 downstream of mTOR in activated cells from patients than in those from healthy control subjects (Fig. 4c,d and Supplementary Fig.  8a ), and that was true even in purified and activated naive CD8 + T cells (data not shown). To confirm that the increased phosphorylation of S6 in cells from patients was achieved via mTORC1, we also examined the extent of phosphorylation at the mTORC1-specific 30 sites Ser240 and Ser244 of S6. Similar to the sites Ser235 and Ser236, the sites Ser240 and Ser244 on S6 were hyperphosphorylated in cultured T cell blasts from patients (Fig. 4e) . Moreover, that phosphorylation was greatly diminished by inhibition of either p110d or mTORC1 through the use of IC87114 or rapamycin, respectively (Fig. 4e) , which supported the conclusion that hyperactive PI(3)K drove the hyperactivation of mTOR in cells from patients. As further support of that conclusion, we measured the phosphorylation of S6 at Ser235 and Ser236 in cells preincubated in phosphate-buffered saline (PBS) for removal of the glucose and amino acids needed to maintain mTOR activity. Indeed, we found that the observed hyperphosphorylation of S6 was lost under those conditions (Supplementary Fig. 8b ), consistent with a requisite role for mTOR in the hyperphosphorylation of S6. As hypothesized from the hyper- inactive form of p110d exhibit impaired antigen receptor signaling in B cells and T cells and attenuated immune responses but also develop inflammatory bowel disease 31 . Moreover, mice that lack p85a show impaired development and activation of B cells but normal activation of T cells under the conditions tested 32, 33 . Similarly, patients deficient in the p85a subunit of PI(3)K also lack B cells and serum immunoglobulins 34 . T cell-specific deletion of PTEN in mice results in hyperactivation of the PI(3)K pathway and causes a lethal lymphoproliferative disease 35 . In human cancers, activating mutations in genes encoding PI(3)K proteins (most frequently p110a) are common, consistent with the role of these proteins in proliferation and survival 36, 37 . Enhanced PI(3)K activity has also been observed in hematopoietic cancers due to oncogenic activation of upstream regulators 38 , which has prompted investigation of p110d-specific inhibitors for therapeutic use 39 . However, the full phenotypic effect of inherited lesions in PIK3CD in humans has not been described. We have now reported the identification of patients heterozygous for one of three different germline mutations in PIK3CD in a cohort of fourteen patients from seven families with an unusual combination of lymphoproliferation and immunodeficiency. Our patients generally presented in childhood with combined immunodeficiency in T cells and B cells and peripheral expansion of lymphocyte populations. A major hallmark of this disease is the appearance of T cell-and B cell-positive lymphoid nodules on respiratory and gastrointestinal mucosal surfaces, a phenotype that is notable given data linking PI(3)K and Akt to the regulation of T cell trafficking 40 . We noted generally low CD4 + T cell counts, and we observed profound defects in mitogen and antigen recall responses. Common to all patients were viremia due to EBV and/or CMV (consistent with T cell defects) and recurrent sinopulmonary infections (consistent with humoral defects). The B cell abnormalities included the accumulation of transitional B cells, a paucity of memory B cells and defects in the secretion of class-switched immunoglobulins, consistent with a role for PI(3)K in the development and maturation of B cells 41, 42 . EBV + lymphoma was diagnosed in two patients, and an additional two patients in these families died from lymphoma before our discovery of this genetic lesion. Investigation of patients who share this phenotype revealed three different gain-of-function mutations in PIK3CD. By structural comparison to the p110a mutants encoded by gain-offunction mutations, we surmised that the substitutions E525K (in the helical domain) and N334K (in the C2 domain) in p110d of our patients probably disrupt specific inhibitory contacts between p110d and the inter-SH2 and N-terminal SH2 domains of p85a, respectively 5, 23, 24, 43 . In contrast, the E1021K substitution of p110d in our patients probably enhances the recruitment of p110d to the plasma membrane and increases its catalytic activity 22, 23, 25 .
Because our patients are unable to control infection with EBV and/or CMV , we focused our studies on CD8 + T cells and unexpectedly found that total and virus-specific CD8 + T cell populations were expanded, with enrichment for phenotypically antigen-experienced CD8 + T cells. However, we observed that patient CD8 + T cells were severely impaired in in vitro proliferation and IL-2 secretion despite hyperphosphorylation of Akt. Akt activity is widely known to promote cell growth, proliferation and metabolism, hence its major role in tumorigenesis 36 . Thus, we were initially surprised that hyperactivation of this pathway resulted in an immunodeficiency with profound defects in in vitro T cell proliferation and IL-2 production. On closer examination, we found that many aspects of TCR signaling were intact but that T cells from patient blood were skewed toward senescent (CD57 + ) and terminally differentiated T EMRA or T EM cells. Thus, we hypothesized that the hyperactive p110d-Akt-mTOR pathway was promoting aerobic glycolysis Treatment of disease with rapamycin As aerobic glycolysis is induced after T cell activation 6 and is incompatible with the maintenance of resting naive T cells 12 , we hypothesized that in vivo treatment of patients who express mutant p110d with rapamycin to inhibit mTOR (and therefore glycolysis) would enable the persistence of naive T cells. After treating patient A.1 (the most severely affected patient with extreme lymphoproliferation) with rapamycin (maintaining trough drug concentrations of 15 ng/ml), we observed a reduction in CD8 + T cell counts to normal numbers within approximately 4 months and noted an increase in the frequency of naive T cells among PBMCs (Fig. 5a,b) . That effect was specific, as CD4 + T cells, which did not expand their populations in the patients, showed no decrease in number after rapamycin therapy (Fig. 5a) . Consistent with the 'rescue' of naive T cells in the peripheral blood, we found nearly complete restoration of IL-2 secretion and proliferative responses after in vitro TCR ligation (Fig. 5c,d) . Clinically, we observed a reduction in hepatospenomegaly and lymphadenopathy (Supplementary Fig. 9 ). Thus, in vivo administration of an mTOR inhibitor improved the derangements of the immune system induced by gain-of-function mutation of the gene encoding p110d by modulating the cell populations in patient blood to restore a more normal balance of naive, effector and memory CD8 + T cell populations. Together these data support the hypothesis that enhanced activity of p110d due to a genetic alteration elicits a lymphoproliferative immunodeficiency caused by mTOR-dependent skewing of T cells to a senescent effector phenotype (Fig. 6) , which can be reversed pharmacologically by rapamycin.
DISCUSSION
Studies of animal models have suggested that impaired PI(3)K signaling leads to immunodeficiency and inflammation, whereas unrestrained PI(3)K signaling contributes to autoimmunity and hematological malignancy 1 . However, that simplistic dichotomy does not fully explain the effects of PI(3)K. Mice that express a catalytically (the Warburg effect 7, 8 ), limiting the function and survival of memory T cells 6, 7, 12, 17 and driving the senescence of CD8 + T cells 15, 44 . Indeed, our patients exhibited p110d-and mTOR-dependent hyperphosphorylation of S6 and increased glucose uptake by cultured T cell blasts, which confirmed that cell-intrinsic mTOR signaling was enhanced by the gain-of-function mutations in these patients. Thus, over time, patients respond ineffectively to infections by inducing the terminal differentiation of CD8 + T cells into senescent effector cells without supporting the development of functional long-lived memory cells. As it is widely accepted that memory T cells are critical for control of chronic infections, the poor anti-EBV and anti-CMV immunity of our patients is probably at least partially due to a diminished pool of functional long-lived memory CD8 + T cells 45 . Additionally, the mTOR-driven differentiation into effector cells could explain the lymphadenopathy, as skewing toward effector-type cells may result in an enhanced proliferative burst upon encounter with antigen. The data reported above provided a rationale for the use of rapamycin therapy to inhibit mTOR, similar to interventions in specific cancers 46 . Although our experience with this intervention is limited at present, in patient A.1, rapamycin produced notable clinical improvement in lymphoproliferation and was associated with nearly normalization of peripheral T cell populations as well as better proliferation and IL-2 secretion by CD8 + T cells in vitro. The restoration of naive T cell and T CM cell populations supports our hypothesis that metabolic effects of mTOR have a central role in causing immunodeficiency. These findings raise the possibility that p110d-specific inhibitors that have described 47 would also be effective in treating this disease clinically and may in fact have better efficacy than rapamycin, as other, mTOR-independent pathways downstream of PI(3)K would also be targeted.
Although the possibility exists that chronic infection with EBV and/ or CMV contributed to the appearance of CD57 + CD8 + T cells, we were unable to find a correlation between viral load and skewing of CD8 + T cells. Our studies of another immunodeficiency associated with EBV, XMEN disease, have revealed normal CD57 expression on CD8 + T cells despite viral loads higher than those noted in the disease described here (data not shown). We also noted that the patients most affected clinically (A.1 and G.1) also had signs of the greatest mTOR activity (i.e., phosphorylation of S6 and glucose uptake). Moreover, treatment with rapamycin partially normalized T cell populations, which again supported the proposal of a cell-intrinsic, mTOR-driven mechanism of effector differentiation and senescence rather than effects of chronic viremia.
In conclusion, we have identified a previously unknown human immunodeficiency we have called 'PASLI disease' ('p110d-activating mutation causing senescent T cells, lymphadenopathy and immunodeficiency'). This disease is caused by dominant, gain-of-function mutations in PIK3CD that promote mTOR-mediated intrinsic CD8 + T cell defects that explain, at least partially, the immunological phenotypes of such patients. Our findings position p110d as a critical participant in the regulation of immunity in humans.
Note added in proof:
Another study has now independently described a cohort of patients with the E1021K substitution of p110δ 48 .
METHODS
Methods and any associated references are available in the online version of the paper. 
